Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE), a clinical-stage drug development company specializing in novel therapeutics for degenerative retinal diseases, will participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025.

The company's executive management team will deliver two presentations: an on-demand corporate presentation at 7:00 AM ET and participate in a panel discussion on "Pivotal-Stage Assets for Retinal Disorders" at 11:00 AM ET. Both presentations will be accessible via webcast through Belite Bio's investor relations website, with replays available for 90 days.

News Market Reaction – BLTE

+2.53%

2 alerts

+2.53% News Effect

+$59M Valuation Impact

$2.40B Market Cap

0.5x Rel. Volume

On the day this news was published, BLTE gained 2.53%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $59M to the company's valuation, bringing the market cap to $2.40B at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows:

• 7:00 am ET, on-demand corporate presentation
• 11:00 am ET, “Pivotal-Stage Assets for Retinal Disorders” panel discussion

Webcast Link Instructions
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

When is Belite Bio (BLTE) presenting at the H.C. Wainwright Ophthalmology Conference 2025?

Belite Bio will present twice on August 13, 2025: an on-demand corporate presentation at 7:00 AM ET and a panel discussion at 11:00 AM ET.

Where can I watch Belite Bio's (BLTE) H.C. Wainwright conference presentations?

The presentations can be accessed through the webcast link under the 'Events' tab on Belite Bio's investor relations website at investors.belitebio.com. Replays will be available for 90 days.

What topics will Belite Bio (BLTE) discuss at the H.C. Wainwright conference?

Belite Bio will participate in a panel discussion on 'Pivotal-Stage Assets for Retinal Disorders' and deliver a corporate presentation about their development of therapeutics for degenerative retinal diseases.

How long will Belite Bio's (BLTE) conference presentations be available for replay?

The presentation replays will be archived for 90 days following the August 13, 2025 presentation date.